Anabolic Steroids Blog - iSteroids . com » Continued benefit from asthma drugs require regular doses

Continued benefit from asthma drugs require regular doses

Continued benefit from asthma drugs require regular doses According to new results from a comprehensive childhood asthma study, asthmatic children who benefited from steroid drugs are unable to experience the same results after discontinuing the usage.

The findings of this study came from the Childhood Asthma Management Program (CAMP) clinical trial in which more than 1,000 children were treated for mild-to-moderate asthma. Children were divided into three groups in which one group received twice-daily budesonide and an inhaled corticosteroid medication, the second group received a placebo and the third group received nedocromil (an inhaled non-steroid medication). All the three groups also received albuterol, a bronchodilator, and oral corticosteroids for treating asthma symptoms.

From News-Medical.Net:

Inhaled corticosteroids such as budesonide have been shown to be the most effective form of anti-inflammatory treatment for asthma by controlling symptoms and improving pulmonary function. Results from the original CAMP trial showed that using budesonide twice daily led to fewer hospitalizations and urgent care visits, fewer days in which additional asthma medications were needed and a reduced need for albuterol, a fast-acting drug for relief of acute asthma symptoms. Using nedocromil twice daily reduced urgent care visits and courses of oral steroids for severe symptoms, but did not affect the number of hospitalizations, symptoms or airway responsiveness.

Although the patients had fewer symptoms five years after stopping the daily medication, Strunk cautions that doesn’t mean that they can stop using asthma medications altogether or that their asthma is cured.

In another part of the follow-up study, the involved researchers had a close look at the long-term side effects of the steroid therapy on bone density, fracture rate, and growth.

The study is expected to provide deep insights to the medical fraternity to formulate new plans for treating asthma, which is considered to affect more than 150,000 people in the United States alone.